-
1 week ago | 
healio.com | Mark Leiser
Key takeaways: CAN-2409 plus valacyclovir nearly doubled survival compared with docetaxel for patients who had inadequate response to immune checkpoint inhibitors. Patients with nonsquamous histology derived greater benefit. An investigational viral immunotherapy extended survival compared with standard care for patients with advanced non-small cell lung cancer who had inadequate response to immune checkpoint inhibitor therapy, phase 2 trial results showed.
-
4 weeks ago | 
healio.com | Mark Leiser |Heather Biele |Gabrielle B. Rocque
Gabrielle B. Rocque, MD, MSPH, FASCO These investigators aimed to determine if a remote symptom monitoring program using electronic patient-reported outcomes improves fatigue among patients with metastatic breast cancer. This is an incredibly patient-centric question. Seventy percent of people in the study population had visceral disease and approximately half were on chemotherapy.
-
1 month ago | 
healio.com | Jennifer Byrne |Mark Leiser
Key takeaways: More than half of individuals with lymphoma or multiple myeloma reported clinically significant anxiety or depression symptoms. Researchers recommended early screening for newly diagnosed patients. More than half of patients recently diagnosed with lymphoma or myeloma had clinically significant symptoms of anxiety or depression, according to study results. Those symptoms correlated with reduced quality of life. Oreofe O.
-
1 month ago | 
healio.com | Jennifer Byrne |Mark Leiser
The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among certain patients with breast cancer, according to findings published in Nature Medicine. The randomized phase 3 CheckMate 7FL trial included 510 patients with high-risk, early-stage ER-positive, HER2-negative breast cancer.
-
1 month ago | 
healio.com | Jennifer Byrne |Mark Leiser |Donald Patrick
Key takeaways: Most people who used multicancer early detection tests reported high levels of satisfaction. Increases in anxiety after receipt of test results returned toward baseline at 12 months. The vast majority of individuals who used multicancer early detection tests reported being satisfied with the test, according to data from a prospective, multicenter cohort study.
-
1 month ago | 
healio.com | Mark Leiser |Heather Biele |Premal Thaker
Premal H. Thaker, MD There have been many retrospective reports evaluating the benefit of radiation vs. cisplatin with concurrent radiation for patients with intermediate-risk criteria. In GOG-263, Ryu and colleagues prospectively evaluated this clinical question, and approximately 85% of patients could compete six cycles of cisplatin with concurrent chemoradiation.
-
1 month ago | 
healio.com | Tarun Kumar |Jennifer Byrne |Matthew Shinkle |Mark Leiser
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
-
1 month ago | 
healio.com | Mark Leiser
Key takeaways:Healio is the official media partner for the CancerX 2025 Accelerator cohort. The cohort is comprised of innovative startups focused on addressing critical challenges in oncology. Healio is pleased to announce its partnership with CancerX, a public-private collaboration dedicated to the acceleration of innovation in cancer treatment.
-
1 month ago | 
healio.com | Mark Leiser |Heather Biele
Key takeaways: Eighty percent of patients achieved clinical complete response to nivolumab. Researchers observed no recurrences during follow-up. PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer showed. Nivolumab (Opdivo, Bristol Myers Squibb) induced “meaningful complete response” among those with mismatch repair-deficient disease, according to researchers.
-
1 month ago | 
healio.com | Mark Leiser |Heather Biele
Key takeaways: Twelve of 28 evaluable women achieved partial response after treatment with cadonilimab and lenvatinib. Seven patients experienced grade 3/grade 4 adverse events. A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer showed.
